AtriCure, Inc. (NASDAQ:ATRC) Soars 29% But It's A Story Of Risk Vs Reward
AtriCure Touts First Case With New FDA-cleared AtriClip Flex-Mini
AtriCure Reports First Patient Has Been Treated With The Revolutionary AtriClip FLEX-Mini Device
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?
AtriCure Receives Expanded Indication For AtriClip In Europe For High-Risk Thromboembolism Patients, Validating Its Effectiveness In Reducing Stroke Events During Cardiac Surgery
AtriCure Receives Expanded CE-Mark Indication for AtriClip Devices for the Reduction of Stroke in Patients With Atrial Fibrillation
CCORF Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $49
CCORF analyst William Plovanic maintains $AtriCure(ATRC.US)$ with a buy rating, and maintains the target price at $49.According to TipRanks data, the analyst has a success rate of 40.8% and a total
Atricure's Market Strength and Innovation Justify Buy Rating
US$39.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results
US$40.89: That's What Analysts Think AtriCure, Inc. (NASDAQ:ATRC) Is Worth After Its Latest Results
AtriCure Second Quarter 2024 Earnings: EPS Misses Expectations
Oppenheimer Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $32
Oppenheimer analyst Suraj Kalia maintains $AtriCure(ATRC.US)$ with a buy rating, and maintains the target price at $32.According to TipRanks data, the analyst has a success rate of 52.1% and a total
Navigating 6 Analyst Ratings For AtriCure
AtriCure Price Target Cut to $53.00/Share From $58.00 by BTIG
AtriCure Is Maintained at Buy by BTIG
JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $30
AtriCure | 10-Q: Q2 2024 Earnings Report
A Quick Look at Today's Ratings for AtriCure(ATRC.US), With a Forecast Between $26 to $60
On Jul 31, major Wall Street analysts update their ratings for $AtriCure(ATRC.US)$, with price targets ranging from $26 to $60.Oppenheimer analyst Suraj Kalia maintains with a buy rating, and
Needham Maintains Buy on AtriCure, Lowers Price Target to $34
AtriCure Is Maintained at Overweight by Piper Sandler